Australia New Zealand Gynaecological Oncology Group

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Private

Established: 2000-01-01

Employees: 11

Market Cap: -

Website: https://www.anzgog.org.au

Clinical Trials

EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

Phase 2

Recruiting

Conditions: Ovarian Carcinosarcoma
Uterine Carcinosarcoma

Interventions: Drug: Eribulin Mesylate
Drug: Pembrolizumab

First Posted Date: 2022-11-17

Last Posted Date: 2024-02-08

Lead Sponsor: Australia New Zealand Gynaecological Oncology Group

Target Recruit Count: 30

Registration Number: NCT05619913

Locations: 🇦🇺
Prince of Wales Hospital, Randwick, New South Wales, Australia
🇬🇧
Imperial College London, London, United Kingdom
🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia

and more 3 locations

Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy

Phase 2

Withdrawn

Conditions: Metastatic Cervical Cancer

Interventions: Drug: Tislelizumab
Drug: Sitravatinib

First Posted Date: 2022-11-14

Last Posted Date: 2023-06-29

Lead Sponsor: Australia New Zealand Gynaecological Oncology Group

Registration Number: NCT05614453

Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy

Phase 2

Withdrawn

Conditions: Ovarian Cancer
Carcinosarcoma

Interventions: Drug: Pamiparib

First Posted Date: 2019-05-01

Last Posted Date: 2021-08-10

Lead Sponsor: Australia New Zealand Gynaecological Oncology Group

Registration Number: NCT03933761

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy